Liver Cell Carcinoma
Also known as: Hepatocellular Carcinoma(HCC) / Hepato-cellular Carcinoma / Liver Carcinoma / Carcinoma; Hepatocellular / Carcinoma Liver / HCC (Hepatocellular Carcinoma) / Carcinoma. Hepatocellular / Hepatocellular Carcinoma (HCC) / Hepato Cellular Carcinoma / HCC (Hepatocellular Carcinoma / Carcinoma,Hepatocellular / Hepatocellular,Carcinoma / Carcinoma, Hepatocellular (RENI) / HCC - Hepatocellular Carcinoma / Hepatocellular Carcinoma (Hepatoma) / Hepatocarcinoma / Hepatocellular Carcinoma / Hepatic Carcinoma / Hepato Cellular Carcinoma (HCC) / Hepatic carcinomas / Hepatocellular Carcinomas / Hepatocellular Carcinomas (HCC) / Carcinoma, Hepatocellular / Carcinoma hepatocellular / Primary liver cell carcinoma (disorder) / Hepatoma / Primary carcinoma of liver (disorder) / Liver cell carcinoma (disorder) / Hepatocellular carcinoma (morphologic abnormality) / Carcinoma of liver / Liver tumour NOS / Liver tumor NOS / Tumor liver / Tumour liver / Liver tumor / Hepatic neoplasm NOS / Liver tumour / Hepatic neoplasm / Liver neoplasm / Liver Neoplasms / Neoplasm of liver (disorder) / Neoplasm liver / Hepatic neoplasia / Malignant neoplasm of liver, not specified as primary or secondary / Hepatic cancer / Hepatic tumour malignant / Hepatic tumor malignant / Liver, cancer of / Cancer of Liver / Malignant liver tumour / Malignant liver tumor / Hepatic neoplasm malignant NOS / Malignant hepatic neoplasm / Hepatic neoplasms malignant / Hepatic neoplasm malignant / Malignant neoplasm of liver (disorder)
Drug | Drug Name | Drug Description |
---|---|---|
DB08875 | Cabozantinib | A tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. |
DB01101 | Capecitabine | A nucleoside metabolic inhibitor indicated to treat different gastrointestinal, including pancreatic cancer, and breast cancer. |
DB06186 | Ipilimumab | A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. |
DB09035 | Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
DB05578 | Ramucirumab | An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. |
DB08896 | Regorafenib | A kinase inhibitor used to treat patients with metastatic colorectal cancer, unresectable, locally advanced, or metastatic gastrointestinal stromal tumors, and hepatocellular carcinoma. |